NASDAQ:SRPT Sarepta Therapeutics Q2 2025 Earnings Report $23.38 +0.26 (+1.12%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$23.24 -0.14 (-0.60%) As of 05:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Sarepta Therapeutics EPS ResultsActual EPS$2.02Consensus EPS $0.89Beat/MissBeat by +$1.13One Year Ago EPS$0.07Sarepta Therapeutics Revenue ResultsActual Revenue$611.09 millionExpected Revenue$530.66 millionBeat/MissBeat by +$80.43 millionYoY Revenue Growth+68.40%Sarepta Therapeutics Announcement DetailsQuarterQ2 2025Date8/6/2025TimeAfter Market ClosesConference Call DateWednesday, August 6, 2025Conference Call Time4:00PM ETUpcoming EarningsSarepta Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Sarepta Therapeutics Earnings HeadlinesWhat's Going On Sarepta Stock On Wednesday?October 8 at 11:19 AM | benzinga.comA Look at Sarepta Therapeutics (SRPT) Valuation Following Recent Share Price GainsOctober 6 at 9:47 AM | finance.yahoo.comURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed. | StockEarnings (Ad)Sarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial ResultsOctober 3, 2025 | insidermonkey.comSarepta: Q3 Earnings An Upcoming Catalyst, But Risks Undermine Any Contrarian PlayOctober 3, 2025 | seekingalpha.comSarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society CongressOctober 3, 2025 | businesswire.comSee More Sarepta Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sarepta Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sarepta Therapeutics and other key companies, straight to your email. Email Address About Sarepta TherapeuticsSarepta Therapeutics (NASDAQ:SRPT) is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities. Sarepta’s commercial products include several exon-skipping therapies approved by the U.S. Food and Drug Administration for specific DMD mutations. Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen) use chemically modified oligonucleotides to induce exon skipping and restore production of functional dystrophin protein. In addition, Elevidys (delandistrogene moxeparvovec) is an adeno-associated virus (AAV)-based gene therapy designed to deliver a shortened dystrophin gene to muscle tissue, representing one of the first approved gene therapies for DMD. Founded in the late 1980s under the name AVI BioPharma and rebranded as Sarepta Therapeutics in 2012, the company initially explored antiviral technologies before pivoting to neuromuscular disease in 2010. Sarepta now maintains commercial operations across North America and has established collaborations in Europe and Asia to support clinical trials and regulatory filings. The company continues to expand its pipeline, exploring next-generation gene editing, microdystrophin constructs and treatments for other genetic muscle disorders such as limb-girdle muscular dystrophy. Leadership at Sarepta is spearheaded by President and Chief Executive Officer Douglas Ingram, who joined the company in 2018 and assumed the CEO role in 2021. Under his guidance, Sarepta has grown from a single-product organization into a multi-asset innovator with a broad platform in precision genetic medicine. The company’s executive team combines expertise in neurology, genetic engineering and regulatory affairs to advance therapies from early-stage research through global commercialization.View Sarepta Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)BlackRock (10/14/2025)ASML (10/15/2025)Kinder Morgan (10/15/2025)Bank of America (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
